Skip to content or view screen version

Investigation into LSR (HLS)

SHAC | 11.05.2009 22:41 | SHAC | Analysis | Animal Liberation | Social Struggles | Cambridge | World

Finkelstein Thompson LLP is currently investigating possible shareholder claims arising from potential breaches of fiduciary duty by certain executives and directors of Life Sciences Research, Inc. (NYSE: LSR) in connection with the proposal by Andrew Baker, LSR's Chairman and Chief Executive Officer, to acquire all of the outstanding shares of LSR for a price of $7.50 per share pursuant to a letter dated March 3, 2009. See

The investigation is focused on the possible inadequacy of the consideration to be paid to the public shareholders as well as the potential unfairness of the procedures followed by the Board in connection with this proposal.

The firm has served in cases that recovered over $1 billion for investors and consumers.

More info

- e-mail:
- Homepage: